IL133212A - History of use (imidazolil-5-yl) methyl-2-quinolinone that act as culture inhibitors of smooth muscle cells - Google Patents

History of use (imidazolil-5-yl) methyl-2-quinolinone that act as culture inhibitors of smooth muscle cells

Info

Publication number: IL133212A
Authority: IL; Israel
Prior art keywords: sub; 6alkyl; sup; alkyl; hydrogen
Prior art date: 1997-06-02

Application number

IL13321298A

Other languages

English (en)

Hebrew (he)

Other versions

IL133212A0 (en

Original Assignee

Janssen Pharmaceutica Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-06-02

Filing date

1998-05-25

Publication date

2005-12-18

1998-05-25 Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv

2001-03-19 Publication of IL133212A0 publication Critical patent/IL133212A0/xx

2005-12-18 Publication of IL133212A publication Critical patent/IL133212A/en

Links

210000000329 smooth muscle myocyte Anatomy 0.000 title claims abstract description 23
230000004663 cell proliferation Effects 0.000 title claims abstract description 14
AVGQUILLCRPWKH-UHFFFAOYSA-N 4-(1h-imidazol-5-yl)-3-methyl-1h-quinolin-2-one Chemical class C12=CC=CC=C2NC(=O)C(C)=C1C1=CN=CN1 AVGQUILLCRPWKH-UHFFFAOYSA-N 0.000 title 1
150000001875 compounds Chemical class 0.000 claims abstract description 136
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 80
239000001257 hydrogen Substances 0.000 claims abstract description 79
-1 amino, hydroxycarbonyl Chemical group 0.000 claims abstract description 62
150000002431 hydrogen Chemical class 0.000 claims abstract description 49
125000004356 hydroxy functional group Chemical group O* 0.000 claims abstract description 27
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 11
125000004093 cyano group Chemical group *C#N 0.000 claims abstract description 11
239000001301 oxygen Substances 0.000 claims abstract description 11
229910052760 oxygen Inorganic materials 0.000 claims abstract description 11
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 10
239000003814 drug Substances 0.000 claims abstract description 10
125000002883 imidazolyl group Chemical group 0.000 claims abstract description 8
238000004519 manufacturing process Methods 0.000 claims abstract description 6
125000004951 trihalomethoxy group Chemical group 0.000 claims abstract description 6
125000004953 trihalomethyl group Chemical group 0.000 claims abstract description 5
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract description 4
229910052717 sulfur Chemical group 0.000 claims abstract description 4
239000011593 sulfur Chemical group 0.000 claims abstract description 4
ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical group O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 claims abstract description 3
125000001475 halogen functional group Chemical group 0.000 claims abstract 13
239000002253 acid Substances 0.000 claims description 23
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 21
150000003839 salts Chemical class 0.000 claims description 18
208000037803 restenosis Diseases 0.000 claims description 17
238000000576 coating method Methods 0.000 claims description 16
239000011248 coating agent Substances 0.000 claims description 15
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 12
230000002062 proliferating effect Effects 0.000 claims description 12
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 11
230000002792 vascular Effects 0.000 claims description 10
239000000463 material Substances 0.000 claims description 9
150000001413 amino acids Chemical class 0.000 claims description 7
238000007887 coronary angioplasty Methods 0.000 claims description 6
201000001320 Atherosclerosis Diseases 0.000 claims description 5
125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 5
210000004351 coronary vessel Anatomy 0.000 claims description 5
101100490437 Mus musculus Acvrl1 gene Proteins 0.000 claims description 3
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 2
PLHJCIYEEKOWNM-UHFFFAOYSA-N 6-[amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one Chemical compound CN1C=NC=C1C(N)(C=1C=C2C(C=3C=C(Cl)C=CC=3)=CC(=O)N(C)C2=CC=1)C1=CC=C(Cl)C=C1 PLHJCIYEEKOWNM-UHFFFAOYSA-N 0.000 claims 1
125000000217 alkyl group Chemical group 0.000 abstract description 34
125000003545 alkoxy group Chemical group 0.000 abstract 9
125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 4
125000003342 alkenyl group Chemical group 0.000 abstract 1
125000004414 alkyl thio group Chemical group 0.000 abstract 1
239000000203 mixture Substances 0.000 description 102
239000000543 intermediate Substances 0.000 description 68
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 56
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 54
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 48
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 47
239000002904 solvent Substances 0.000 description 44
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 42
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 40
239000000243 solution Substances 0.000 description 37
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 36
229910001868 water Inorganic materials 0.000 description 33
239000012044 organic layer Substances 0.000 description 29
239000002244 precipitate Substances 0.000 description 28
239000003480 eluent Substances 0.000 description 26
125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 26
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 25
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
239000000741 silica gel Substances 0.000 description 23
229910002027 silica gel Inorganic materials 0.000 description 23
238000004440 column chromatography Methods 0.000 description 22
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 21
238000000034 method Methods 0.000 description 20
239000002585 base Substances 0.000 description 19
VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 18
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 17
150000003254 radicals Chemical class 0.000 description 17
MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 16
239000000047 product Substances 0.000 description 16
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
238000006243 chemical reaction Methods 0.000 description 15
125000005843 halogen group Chemical group 0.000 description 14
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 13
210000001367 artery Anatomy 0.000 description 13
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 12
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 12
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 11
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
235000011114 ammonium hydroxide Nutrition 0.000 description 11
125000001309 chloro group Chemical group Cl* 0.000 description 11
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 10
ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 10
238000000746 purification Methods 0.000 description 10
238000003756 stirring Methods 0.000 description 10
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 10
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
210000004027 cell Anatomy 0.000 description 9
108010037444 diisopropylglutathione ester Proteins 0.000 description 9
208000035475 disorder Diseases 0.000 description 9
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 8
238000002399 angioplasty Methods 0.000 description 8
HTZCNXWZYVXIMZ-UHFFFAOYSA-M benzyl(triethyl)azanium;chloride Chemical compound [Cl-].CC[N+](CC)(CC)CC1=CC=CC=C1 HTZCNXWZYVXIMZ-UHFFFAOYSA-M 0.000 description 8
239000003153 chemical reaction reagent Substances 0.000 description 8
XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 7
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical class OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 7
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 7
GHQPBDDZGPAVJP-UHFFFAOYSA-N azanium;methanol;hydroxide Chemical compound N.O.OC GHQPBDDZGPAVJP-UHFFFAOYSA-N 0.000 description 7
125000000524 functional group Chemical group 0.000 description 7
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 7
239000010410 layer Substances 0.000 description 7
239000011591 potassium Substances 0.000 description 7
229910052700 potassium Inorganic materials 0.000 description 7
LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical group C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 7
230000009466 transformation Effects 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
MUBZPKHOEPUJKR-UHFFFAOYSA-L Oxalate Chemical compound [O-]C(=O)C([O-])=O MUBZPKHOEPUJKR-UHFFFAOYSA-L 0.000 description 6
235000001014 amino acid Nutrition 0.000 description 6
229940024606 amino acid Drugs 0.000 description 6
QARVLSVVCXYDNA-UHFFFAOYSA-N bromobenzene Chemical compound BrC1=CC=CC=C1 QARVLSVVCXYDNA-UHFFFAOYSA-N 0.000 description 6
125000004432 carbon atom Chemical group C* 0.000 description 6
DCFKHNIGBAHNSS-UHFFFAOYSA-N chloro(triethyl)silane Chemical compound CC[Si](Cl)(CC)CC DCFKHNIGBAHNSS-UHFFFAOYSA-N 0.000 description 6
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 6
229910052757 nitrogen Inorganic materials 0.000 description 6
229910000027 potassium carbonate Inorganic materials 0.000 description 6
238000002360 preparation method Methods 0.000 description 6
229930185107 quinolinone Natural products 0.000 description 6
238000012360 testing method Methods 0.000 description 6
210000001519 tissue Anatomy 0.000 description 6
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 5
230000002378 acidificating effect Effects 0.000 description 5
229960005235 piperonyl butoxide Drugs 0.000 description 5
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical class [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
150000007513 acids Chemical class 0.000 description 4
239000000560 biocompatible material Substances 0.000 description 4
229910052799 carbon Inorganic materials 0.000 description 4
230000007062 hydrolysis Effects 0.000 description 4
238000006460 hydrolysis reaction Methods 0.000 description 4
239000012442 inert solvent Substances 0.000 description 4
150000002576 ketones Chemical class 0.000 description 4
229920000642 polymer Polymers 0.000 description 4
229920000137 polyphosphoric acid Polymers 0.000 description 4
229920001296 polysiloxane Polymers 0.000 description 4
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
239000003826 tablet Substances 0.000 description 4
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
239000000654 additive Substances 0.000 description 3
150000001408 amides Chemical class 0.000 description 3
SMWDFEZZVXVKRB-UHFFFAOYSA-N anhydrous quinoline Natural products N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 3
239000002775 capsule Substances 0.000 description 3
150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
239000003937 drug carrier Substances 0.000 description 3
239000003527 fibrinolytic agent Substances 0.000 description 3
239000005457 ice water Substances 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
230000006715 negative regulation of smooth muscle cell proliferation Effects 0.000 description 3
150000001282 organosilanes Chemical class 0.000 description 3
238000007254 oxidation reaction Methods 0.000 description 3
239000008194 pharmaceutical composition Substances 0.000 description 3
230000000144 pharmacologic effect Effects 0.000 description 3
229920000052 poly(p-xylylene) Chemical class 0.000 description 3
235000015320 potassium carbonate Nutrition 0.000 description 3
235000011181 potassium carbonates Nutrition 0.000 description 3
238000007363 ring formation reaction Methods 0.000 description 3
125000001424 substituent group Chemical group 0.000 description 3
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 3
239000000725 suspension Substances 0.000 description 3
238000000844 transformation Methods 0.000 description 3
IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 2
IKMMPHALUZQNMN-UHFFFAOYSA-N 3-(1h-imidazol-5-ylmethyl)-1h-quinolin-2-one Chemical class O=C1NC2=CC=CC=C2C=C1CC1=CN=CN1 IKMMPHALUZQNMN-UHFFFAOYSA-N 0.000 description 2
125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 2
YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
239000004475 Arginine Substances 0.000 description 2
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
208000037260 Atherosclerotic Plaque Diseases 0.000 description 2
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
239000004472 Lysine Substances 0.000 description 2
238000007126 N-alkylation reaction Methods 0.000 description 2
229910017974 NH40H Inorganic materials 0.000 description 2
URLKBWYHVLBVBO-UHFFFAOYSA-N Para-Xylene Chemical group CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 description 2
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
208000007536 Thrombosis Diseases 0.000 description 2
208000027418 Wounds and injury Diseases 0.000 description 2
150000001298 alcohols Chemical class 0.000 description 2
239000003513 alkali Substances 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
125000003277 amino group Chemical group 0.000 description 2
150000008064 anhydrides Chemical class 0.000 description 2
239000005557 antagonist Substances 0.000 description 2
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
230000017531 blood circulation Effects 0.000 description 2
230000037396 body weight Effects 0.000 description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
229910052794 bromium Inorganic materials 0.000 description 2
239000000969 carrier Substances 0.000 description 2
239000003054 catalyst Substances 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
239000006285 cell suspension Substances 0.000 description 2
229940126214 compound 3 Drugs 0.000 description 2
MLIREBYILWEBDM-UHFFFAOYSA-N cyanoacetic acid Chemical compound OC(=O)CC#N MLIREBYILWEBDM-UHFFFAOYSA-N 0.000 description 2
230000006378 damage Effects 0.000 description 2
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
230000010339 dilation Effects 0.000 description 2
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
239000008103 glucose Substances 0.000 description 2
239000003102 growth factor Substances 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
229960002897 heparin Drugs 0.000 description 2
229920000669 heparin Polymers 0.000 description 2
150000004677 hydrates Chemical class 0.000 description 2
238000011065 in-situ storage Methods 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
208000014674 injury Diseases 0.000 description 2
125000000842 isoxazolyl group Chemical group 0.000 description 2
239000007788 liquid Substances 0.000 description 2
239000002609 medium Substances 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
CKJNUZNMWOVDFN-UHFFFAOYSA-N methanone Chemical compound O=[CH-] CKJNUZNMWOVDFN-UHFFFAOYSA-N 0.000 description 2
QYEMNJMSULGQRD-UHFFFAOYSA-N methyl-1H-quinolin-2-one Natural products C1=CC=C2C=CC(=O)N(C)C2=C1 QYEMNJMSULGQRD-UHFFFAOYSA-N 0.000 description 2
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 2
150000004682 monohydrates Chemical class 0.000 description 2
SQDFHQJTAWCFIB-UHFFFAOYSA-N n-methylidenehydroxylamine Chemical compound ON=C SQDFHQJTAWCFIB-UHFFFAOYSA-N 0.000 description 2
230000008692 neointimal formation Effects 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
150000007530 organic bases Chemical class 0.000 description 2
239000007800 oxidant agent Substances 0.000 description 2
239000006187 pill Substances 0.000 description 2
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
229920002635 polyurethane Polymers 0.000 description 2
239000004814 polyurethane Substances 0.000 description 2
239000000843 powder Substances 0.000 description 2
230000008569 process Effects 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
125000006239 protecting group Chemical group 0.000 description 2
102000016914 ras Proteins Human genes 0.000 description 2
108010014186 ras Proteins Proteins 0.000 description 2
230000008707 rearrangement Effects 0.000 description 2
238000007142 ring opening reaction Methods 0.000 description 2
229930195734 saturated hydrocarbon Natural products 0.000 description 2
239000012279 sodium borohydride Substances 0.000 description 2
229910000033 sodium borohydride Inorganic materials 0.000 description 2
239000012312 sodium hydride Substances 0.000 description 2
229910000104 sodium hydride Inorganic materials 0.000 description 2
239000007787 solid Substances 0.000 description 2
229910001220 stainless steel Inorganic materials 0.000 description 2
239000010935 stainless steel Substances 0.000 description 2
239000007858 starting material Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
229910052715 tantalum Inorganic materials 0.000 description 2
GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 1
IFTMLIXHTKUJCT-UHFFFAOYSA-N (3-butylimidazol-4-yl)-(4-chlorophenyl)methanone Chemical compound CCCCN1C=NC=C1C(=O)C1=CC=C(Cl)C=C1 IFTMLIXHTKUJCT-UHFFFAOYSA-N 0.000 description 1
CLFRUWPJQKSRRT-UHFFFAOYSA-N (4-chlorophenyl)-(4-nitrophenyl)methanone Chemical compound C1=CC([N+](=O)[O-])=CC=C1C(=O)C1=CC=C(Cl)C=C1 CLFRUWPJQKSRRT-UHFFFAOYSA-N 0.000 description 1
PUDHBTGHUJUUFI-SCTWWAJVSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-p Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 PUDHBTGHUJUUFI-SCTWWAJVSA-N 0.000 description 1
GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
DEVSOMFAQLZNKR-RJRFIUFISA-N (z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-n'-pyrazin-2-ylprop-2-enehydrazide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C2=NN(\C=C/C(=O)NNC=3N=CC=NC=3)C=N2)=C1 DEVSOMFAQLZNKR-RJRFIUFISA-N 0.000 description 1
CUJPFPXNDSIBPG-UHFFFAOYSA-N 1,3-propanediyl Chemical group [CH2]C[CH2] CUJPFPXNDSIBPG-UHFFFAOYSA-N 0.000 description 1
OMIVCRYZSXDGAB-UHFFFAOYSA-N 1,4-butanediyl Chemical group [CH2]CC[CH2] OMIVCRYZSXDGAB-UHFFFAOYSA-N 0.000 description 1
MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-methyl-1H-imidazole Chemical compound CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 description 1
IPOVOSHRRIJKBR-UHFFFAOYSA-N 2-ethylpropanedioyl dichloride Chemical compound CCC(C(Cl)=O)C(Cl)=O IPOVOSHRRIJKBR-UHFFFAOYSA-N 0.000 description 1
150000004327 2-hydroxyquinolines Chemical class 0.000 description 1
QKPVEISEHYYHRH-UHFFFAOYSA-N 2-methoxyacetonitrile Chemical compound COCC#N QKPVEISEHYYHRH-UHFFFAOYSA-N 0.000 description 1
RUWFONNAPGDNKZ-UHFFFAOYSA-N 2-methylimidazole-1-sulfonamide Chemical compound CC=1N(C=CN1)S(=O)(=O)N RUWFONNAPGDNKZ-UHFFFAOYSA-N 0.000 description 1
XAEBTCPOZVEMHR-UHFFFAOYSA-N 2-methylpropan-2-ol;potassium Chemical compound [K].CC(C)(C)O XAEBTCPOZVEMHR-UHFFFAOYSA-N 0.000 description 1
SDTMFDGELKWGFT-UHFFFAOYSA-N 2-methylpropan-2-olate Chemical compound CC(C)(C)[O-] SDTMFDGELKWGFT-UHFFFAOYSA-N 0.000 description 1
125000006024 2-pentenyl group Chemical group 0.000 description 1
LSBDFXRDZJMBSC-UHFFFAOYSA-N 2-phenylacetamide Chemical compound NC(=O)CC1=CC=CC=C1 LSBDFXRDZJMBSC-UHFFFAOYSA-N 0.000 description 1
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
FCWLPQWRAKGOGU-UHFFFAOYSA-N 3-(3-chlorophenyl)-n-phenylprop-2-enamide Chemical compound ClC1=CC=CC(C=CC(=O)NC=2C=CC=CC=2)=C1 FCWLPQWRAKGOGU-UHFFFAOYSA-N 0.000 description 1
QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
SRWILAKSARHZPR-UHFFFAOYSA-N 3-chlorobenzaldehyde Chemical compound ClC1=CC=CC(C=O)=C1 SRWILAKSARHZPR-UHFFFAOYSA-N 0.000 description 1
NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
XKTYXVDYIKIYJP-UHFFFAOYSA-N 3h-dioxole Chemical compound C1OOC=C1 XKTYXVDYIKIYJP-UHFFFAOYSA-N 0.000 description 1
KFDVRZXTYQSUSU-UHFFFAOYSA-N 4-(3-chlorophenyl)-3,4-dihydro-1h-quinolin-2-one Chemical compound ClC1=CC=CC(C2C3=CC=CC=C3NC(=O)C2)=C1 KFDVRZXTYQSUSU-UHFFFAOYSA-N 0.000 description 1
DXOWLADCTKQWAD-UHFFFAOYSA-N 4-(3-chlorophenyl)-6-[(4-chlorophenyl)-(methylamino)-(3-methylimidazol-4-yl)methyl]-1-methylquinolin-2-one;hydrate Chemical compound O.C=1C=C(Cl)C=CC=1C(C=1C=C2C(C=3C=C(Cl)C=CC=3)=CC(=O)N(C)C2=CC=1)(NC)C1=CN=CN1C DXOWLADCTKQWAD-UHFFFAOYSA-N 0.000 description 1
OTNGVVFHZIWGMA-UHFFFAOYSA-N 4-(3-chlorophenyl)-6-[(4-chlorophenyl)-hydroxy-(3-methylimidazol-4-yl)methyl]-3-phenyl-1h-quinolin-2-one Chemical compound CN1C=NC=C1C(O)(C=1C=C2C(C=3C=C(Cl)C=CC=3)=C(C=3C=CC=CC=3)C(=O)NC2=CC=1)C1=CC=C(Cl)C=C1 OTNGVVFHZIWGMA-UHFFFAOYSA-N 0.000 description 1
BVPWJMCABCPUQY-UHFFFAOYSA-N 4-amino-5-chloro-2-methoxy-N-[1-(phenylmethyl)-4-piperidinyl]benzamide Chemical compound COC1=CC(N)=C(Cl)C=C1C(=O)NC1CCN(CC=2C=CC=CC=2)CC1 BVPWJMCABCPUQY-UHFFFAOYSA-N 0.000 description 1
XRHGYUZYPHTUJZ-UHFFFAOYSA-N 4-chlorobenzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1 XRHGYUZYPHTUJZ-UHFFFAOYSA-N 0.000 description 1
IDKYCLCDTGIFBA-UHFFFAOYSA-N 6-(4-chlorobenzoyl)-4-(3-chlorophenyl)-1-methylquinolin-2-one Chemical compound C=1C(=O)N(C)C2=CC=C(C(=O)C=3C=CC(Cl)=CC=3)C=C2C=1C1=CC=CC(Cl)=C1 IDKYCLCDTGIFBA-UHFFFAOYSA-N 0.000 description 1
ZLYWVUYGARBCQN-UHFFFAOYSA-N 6-(4-chlorobenzoyl)-4-(3-chlorophenyl)-1h-quinolin-2-one Chemical compound C1=CC(Cl)=CC=C1C(=O)C1=CC=C(NC(=O)C=C2C=3C=C(Cl)C=CC=3)C2=C1 ZLYWVUYGARBCQN-UHFFFAOYSA-N 0.000 description 1
GLQSCHKVJQTPKU-UHFFFAOYSA-N 6-(4-chlorobenzoyl)-4-(3-chlorophenyl)-3,4-dihydro-1h-quinolin-2-one Chemical compound C1=CC(Cl)=CC=C1C(=O)C1=CC=C(NC(=O)CC2C=3C=C(Cl)C=CC=3)C2=C1 GLQSCHKVJQTPKU-UHFFFAOYSA-N 0.000 description 1
VWCLMPOGFAJAFN-UHFFFAOYSA-N 6-(4-chlorobenzoyl)-4-(3-methoxyphenyl)-1-methylquinolin-2-one Chemical compound COC1=CC=CC(C=2C3=CC(=CC=C3N(C)C(=O)C=2)C(=O)C=2C=CC(Cl)=CC=2)=C1 VWCLMPOGFAJAFN-UHFFFAOYSA-N 0.000 description 1
RVGORKULRXOKMN-UHFFFAOYSA-N 6-[(4-chlorophenyl)-(1-methylimidazol-4-yl)methyl]-1-methyl-4-phenylquinolin-2-one Chemical compound CN1C=NC(C(C=2C=CC(Cl)=CC=2)C=2C=C3C(C=4C=CC=CC=4)=CC(=O)N(C)C3=CC=2)=C1 RVGORKULRXOKMN-UHFFFAOYSA-N 0.000 description 1
FZMYWKUUBBMAPB-UHFFFAOYSA-N 6-[(4-chlorophenyl)-(1h-imidazol-5-yl)methyl]-1-methyl-4-phenylquinolin-2-one Chemical compound C=1C(=O)N(C)C2=CC=C(C(C=3N=CNC=3)C=3C=CC(Cl)=CC=3)C=C2C=1C1=CC=CC=C1 FZMYWKUUBBMAPB-UHFFFAOYSA-N 0.000 description 1
HPQBMSVVOVTYBL-UHFFFAOYSA-N 6-bromo-4-(3-chlorophenyl)-2-methoxyquinoline Chemical compound C=12C=C(Br)C=CC2=NC(OC)=CC=1C1=CC=CC(Cl)=C1 HPQBMSVVOVTYBL-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
229940122937 Actin inhibitor Drugs 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
239000005695 Ammonium acetate Substances 0.000 description 1
206010060965 Arterial stenosis Diseases 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
229940127291 Calcium channel antagonist Drugs 0.000 description 1
229920000049 Carbon (fiber) Chemical class 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
229930105110 Cyclosporin A Natural products 0.000 description 1
108010036949 Cyclosporine Proteins 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
108020004414 DNA Proteins 0.000 description 1
SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
229920002943 EPDM rubber Polymers 0.000 description 1
108010061435 Enalapril Proteins 0.000 description 1
102000007317 Farnesyltranstransferase Human genes 0.000 description 1
108010007508 Farnesyltranstransferase Proteins 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
229940123457 Free radical scavenger Drugs 0.000 description 1
230000005526 G1 to G0 transition Effects 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
101710138608 Glycoprotein NB Proteins 0.000 description 1
229940122853 Growth hormone antagonist Drugs 0.000 description 1
239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
108010007267 Hirudins Proteins 0.000 description 1
102000007625 Hirudins Human genes 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
102000012750 Membrane Glycoproteins Human genes 0.000 description 1
108010090054 Membrane Glycoproteins Proteins 0.000 description 1
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
229940122255 Microtubule inhibitor Drugs 0.000 description 1
UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 description 1
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
239000000020 Nitrocellulose Chemical class 0.000 description 1
230000006179 O-acylation Effects 0.000 description 1
238000010934 O-alkylation reaction Methods 0.000 description 1
208000031481 Pathologic Constriction Diseases 0.000 description 1
239000004952 Polyamide Substances 0.000 description 1
229920002732 Polyanhydride Polymers 0.000 description 1
239000004695 Polyether sulfone Substances 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
229920001710 Polyorthoester Polymers 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
108010023197 Streptokinase Proteins 0.000 description 1
RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 1
102000019197 Superoxide Dismutase Human genes 0.000 description 1
108010012715 Superoxide dismutase Proteins 0.000 description 1
101000712605 Theromyzon tessulatum Theromin Proteins 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
229940122388 Thrombin inhibitor Drugs 0.000 description 1
108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
208000024248 Vascular System injury Diseases 0.000 description 1
208000012339 Vascular injury Diseases 0.000 description 1
206010047163 Vasospasm Diseases 0.000 description 1
FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical class O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 1
DPHFJXVKASDMBW-RQRKFSSASA-N [2-[(8s,9r,10s,11s,13s,14s,16r,17r)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate;hydrate Chemical compound O.C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COC(C)=O)(O)[C@@]1(C)C[C@@H]2O DPHFJXVKASDMBW-RQRKFSSASA-N 0.000 description 1
238000006640 acetylation reaction Methods 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
231100000764 actin inhibitor Toxicity 0.000 description 1
238000005917 acylation reaction Methods 0.000 description 1
238000007259 addition reaction Methods 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
125000003282 alkyl amino group Chemical group 0.000 description 1
230000002152 alkylating effect Effects 0.000 description 1
229910045601 alloy Inorganic materials 0.000 description 1
239000000956 alloy Substances 0.000 description 1
229940087168 alpha tocopherol Drugs 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
235000019257 ammonium acetate Nutrition 0.000 description 1
229940043376 ammonium acetate Drugs 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
230000002942 anti-growth Effects 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
230000000340 anti-metabolite Effects 0.000 description 1
230000002927 anti-mitotic effect Effects 0.000 description 1
230000001028 anti-proliverative effect Effects 0.000 description 1
230000000692 anti-sense effect Effects 0.000 description 1
229940100197 antimetabolite Drugs 0.000 description 1
239000002256 antimetabolite Substances 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
229940127218 antiplatelet drug Drugs 0.000 description 1
229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 description 1
239000000010 aprotic solvent Substances 0.000 description 1
239000011260 aqueous acid Substances 0.000 description 1
KXNPVXPOPUZYGB-XYVMCAHJSA-N argatroban Chemical compound OC(=O)[C@H]1C[C@H](C)CCN1C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C1=CC=CC2=C1NC[C@H](C)C2 KXNPVXPOPUZYGB-XYVMCAHJSA-N 0.000 description 1
229960003856 argatroban Drugs 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
239000003849 aromatic solvent Substances 0.000 description 1
229910052785 arsenic Inorganic materials 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
230000000712 assembly Effects 0.000 description 1
238000000429 assembly Methods 0.000 description 1
METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000000975 bioactive effect Effects 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
OIRCOABEOLEUMC-GEJPAHFPSA-N bivalirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 OIRCOABEOLEUMC-GEJPAHFPSA-N 0.000 description 1
108010055460 bivalirudin Proteins 0.000 description 1
229960001500 bivalirudin Drugs 0.000 description 1
ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 1
229960002802 bromocriptine Drugs 0.000 description 1
NOJMTMIRQRDZMT-GSPXQYRGSA-N bromocriptine methanesulfonate Chemical compound CS(O)(=O)=O.C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 NOJMTMIRQRDZMT-GSPXQYRGSA-N 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000000480 calcium channel blocker Substances 0.000 description 1
159000000007 calcium salts Chemical class 0.000 description 1
FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
229960000830 captopril Drugs 0.000 description 1
239000004917 carbon fiber Chemical class 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
150000001733 carboxylic acid esters Chemical class 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
229920002301 cellulose acetate Chemical class 0.000 description 1
230000008859 change Effects 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
238000010568 chiral column chromatography Methods 0.000 description 1
125000000068 chlorophenyl group Chemical group 0.000 description 1
229960001265 ciclosporin Drugs 0.000 description 1
239000011247 coating layer Substances 0.000 description 1
229960001338 colchicine Drugs 0.000 description 1
229940126543 compound 14 Drugs 0.000 description 1
229940125846 compound 25 Drugs 0.000 description 1
229940125878 compound 36 Drugs 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
229930182912 cyclosporin Natural products 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
JVHIPYJQMFNCEK-UHFFFAOYSA-N cytochalasin Natural products N1C(=O)C2(C(C=CC(C)CC(C)CC=C3)OC(C)=O)C3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 JVHIPYJQMFNCEK-UHFFFAOYSA-N 0.000 description 1
ZMAODHOXRBLOQO-UHFFFAOYSA-N cytochalasin-A Natural products N1C(=O)C23OC(=O)C=CC(=O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 ZMAODHOXRBLOQO-UHFFFAOYSA-N 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
229960000958 deferoxamine Drugs 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000008021 deposition Effects 0.000 description 1
229960003957 dexamethasone Drugs 0.000 description 1
229960003657 dexamethasone acetate Drugs 0.000 description 1
229960002344 dexamethasone sodium phosphate Drugs 0.000 description 1
PLCQGRYPOISRTQ-FCJDYXGNSA-L dexamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-FCJDYXGNSA-L 0.000 description 1
125000000664 diazo group Chemical group [N-]=[N+]=[*] 0.000 description 1
FJBFPHVGVWTDIP-UHFFFAOYSA-N dibromomethane Chemical compound BrCBr FJBFPHVGVWTDIP-UHFFFAOYSA-N 0.000 description 1
SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 1
150000004683 dihydrates Chemical class 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
125000006263 dimethyl aminosulfonyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])S(*)(=O)=O 0.000 description 1
229910001873 dinitrogen Inorganic materials 0.000 description 1
238000007598 dipping method Methods 0.000 description 1
238000009826 distribution Methods 0.000 description 1
125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
229960003638 dopamine Drugs 0.000 description 1
239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000013536 elastomeric material Substances 0.000 description 1
238000000921 elemental analysis Methods 0.000 description 1
GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
229960000873 enalapril Drugs 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
238000013171 endarterectomy Methods 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
230000004761 fibrosis Effects 0.000 description 1
238000003818 flash chromatography Methods 0.000 description 1
238000001640 fractional crystallisation Methods 0.000 description 1
239000012458 free base Substances 0.000 description 1
239000012737 fresh medium Substances 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
229910052737 gold Inorganic materials 0.000 description 1
239000010931 gold Substances 0.000 description 1
229940093915 gynecological organic acid Drugs 0.000 description 1
125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
229940006607 hirudin Drugs 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical class C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
238000005984 hydrogenation reaction Methods 0.000 description 1
230000003301 hydrolyzing effect Effects 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
206010020718 hyperplasia Diseases 0.000 description 1
150000002460 imidazoles Chemical class 0.000 description 1
229940125721 immunosuppressive agent Drugs 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
238000002513 implantation Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
229910001026 inconel Inorganic materials 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
239000011630 iodine Substances 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
229910052741 iridium Inorganic materials 0.000 description 1
GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 description 1
230000001678 irradiating effect Effects 0.000 description 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
229960002437 lanreotide Drugs 0.000 description 1
108010021336 lanreotide Proteins 0.000 description 1
CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 description 1
238000004811 liquid chromatography Methods 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
WGOPGODQLGJZGL-UHFFFAOYSA-N lithium;butane Chemical compound [Li+].CC[CH-]C WGOPGODQLGJZGL-UHFFFAOYSA-N 0.000 description 1
238000011068 loading method Methods 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
229910044991 metal oxide Inorganic materials 0.000 description 1
150000004706 metal oxides Chemical class 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
231100000782 microtubule inhibitor Toxicity 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
238000002156 mixing Methods 0.000 description 1
210000000663 muscle cell Anatomy 0.000 description 1
125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
YRRWNBMOJMMXQY-UHFFFAOYSA-N n,n-dimethylimidazole-1-sulfonamide Chemical compound CN(C)S(=O)(=O)N1C=CN=C1 YRRWNBMOJMMXQY-UHFFFAOYSA-N 0.000 description 1
230000035407 negative regulation of cell proliferation Effects 0.000 description 1
HLXZNVUGXRDIFK-UHFFFAOYSA-N nickel titanium Chemical compound [Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni] HLXZNVUGXRDIFK-UHFFFAOYSA-N 0.000 description 1
229910001000 nickel titanium Inorganic materials 0.000 description 1
150000002825 nitriles Chemical class 0.000 description 1
229920001220 nitrocellulos Chemical class 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000003921 oil Substances 0.000 description 1
239000002674 ointment Substances 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
150000002902 organometallic compounds Chemical class 0.000 description 1
AAQXQNYRCWFBIR-UHFFFAOYSA-N oxalic acid;1h-quinolin-2-one Chemical compound OC(=O)C(O)=O.C1=CC=C2NC(=O)C=CC2=C1 AAQXQNYRCWFBIR-UHFFFAOYSA-N 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000002245 particle Substances 0.000 description 1
239000003961 penetration enhancing agent Substances 0.000 description 1
235000019371 penicillin G benzathine Nutrition 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
UWCVGPLTGZWHGS-ZORIOUSZSA-N pergolide mesylate Chemical compound CS(O)(=O)=O.C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 UWCVGPLTGZWHGS-ZORIOUSZSA-N 0.000 description 1
229960001511 pergolide mesylate Drugs 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
238000003408 phase transfer catalysis Methods 0.000 description 1
CYQAYERJWZKYML-UHFFFAOYSA-N phosphorus pentasulfide Chemical compound S1P(S2)(=S)SP3(=S)SP1(=S)SP2(=S)S3 CYQAYERJWZKYML-UHFFFAOYSA-N 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
229910052697 platinum Inorganic materials 0.000 description 1
229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
239000002745 poly(ortho ester) Substances 0.000 description 1
229920002647 polyamide Polymers 0.000 description 1
239000004417 polycarbonate Substances 0.000 description 1
229920000515 polycarbonate Polymers 0.000 description 1
229920000728 polyester Polymers 0.000 description 1
229920006393 polyether sulfone Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
239000012704 polymeric precursor Substances 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
229920006124 polyolefin elastomer Polymers 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
229920001343 polytetrafluoroethylene Polymers 0.000 description 1
239000004810 polytetrafluoroethylene Substances 0.000 description 1
CUQOHAYJWVTKDE-UHFFFAOYSA-N potassium;butan-1-olate Chemical compound [K+].CCCC[O-] CUQOHAYJWVTKDE-UHFFFAOYSA-N 0.000 description 1
239000002243 precursor Substances 0.000 description 1
125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
150000003141 primary amines Chemical class 0.000 description 1
239000000651 prodrug Substances 0.000 description 1
229940002612 prodrug Drugs 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
210000001147 pulmonary artery Anatomy 0.000 description 1
238000006862 quantum yield reaction Methods 0.000 description 1
150000003248 quinolines Chemical class 0.000 description 1
125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
239000002516 radical scavenger Substances 0.000 description 1
239000000376 reactant Substances 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
150000004492 retinoid derivatives Chemical class 0.000 description 1
230000000250 revascularization Effects 0.000 description 1
238000006798 ring closing metathesis reaction Methods 0.000 description 1
210000003752 saphenous vein Anatomy 0.000 description 1
150000003335 secondary amines Chemical class 0.000 description 1
238000010956 selective crystallization Methods 0.000 description 1
150000004756 silanes Chemical class 0.000 description 1
229910052709 silver Inorganic materials 0.000 description 1
239000004332 silver Substances 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000004544 spot-on Substances 0.000 description 1
238000005507 spraying Methods 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
208000037804 stenosis Diseases 0.000 description 1
230000036262 stenosis Effects 0.000 description 1
230000000707 stereoselective effect Effects 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
239000002731 stomach secretion inhibitor Substances 0.000 description 1
229960005202 streptokinase Drugs 0.000 description 1
229960005137 succinic acid Drugs 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
229940124530 sulfonamide Drugs 0.000 description 1
150000003462 sulfoxides Chemical class 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
150000003512 tertiary amines Chemical class 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
229920002725 thermoplastic elastomer Polymers 0.000 description 1
239000003868 thrombin inhibitor Substances 0.000 description 1
230000009424 thromboembolic effect Effects 0.000 description 1
229960000103 thrombolytic agent Drugs 0.000 description 1
229960000187 tissue plasminogen activator Drugs 0.000 description 1
229910052719 titanium Inorganic materials 0.000 description 1
239000010936 titanium Substances 0.000 description 1
AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
229960000984 tocofersolan Drugs 0.000 description 1
239000003558 transferase inhibitor Substances 0.000 description 1
230000000472 traumatic effect Effects 0.000 description 1
125000002889 tridecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
229910052721 tungsten Inorganic materials 0.000 description 1
239000010937 tungsten Substances 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
229960005356 urokinase Drugs 0.000 description 1
239000004474 valine Substances 0.000 description 1
239000012808 vapor phase Substances 0.000 description 1
229940124549 vasodilator Drugs 0.000 description 1
239000003071 vasodilator agent Substances 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
235000012431 wafers Nutrition 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
238000010626 work up procedure Methods 0.000 description 1
235000005074 zinc chloride Nutrition 0.000 description 1
239000011592 zinc chloride Substances 0.000 description 1
235000004835 α-tocopherol Nutrition 0.000 description 1
239000002076 α-tocopherol Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

IL13321298A 1997-06-02 1998-05-25 History of use (imidazolil-5-yl) methyl-2-quinolinone that act as culture inhibitors of smooth muscle cells IL133212A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US4737697P	1997-06-02	1997-06-02
PCT/EP1998/003182 WO1998055124A1 (en)	1997-06-02	1998-05-25	(imidazol-5-yl)methyl-2-quinolinone derivatives as inhibitors of smooth muscle cell proliferation

Publications (2)

Publication Number	Publication Date
IL133212A0 IL133212A0 (en)	2001-03-19
IL133212A true IL133212A (en)	2005-12-18

Family

ID=21948611

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL13321298A IL133212A (en)	1997-06-02	1998-05-25	History of use (imidazolil-5-yl) methyl-2-quinolinone that act as culture inhibitors of smooth muscle cells

Country Status (22)

Country	Link
US (4)	US6365600B1 (zh)
EP (1)	EP0988038B1 (zh)
JP (1)	JP4209472B2 (zh)
KR (1)	KR100517832B1 (zh)
CN (2)	CN1231215C (zh)
AT (1)	ATE222104T1 (zh)
AU (1)	AU740603B2 (zh)
BR (1)	BR9810423A (zh)
CA (1)	CA2290992C (zh)
DE (1)	DE69807222T2 (zh)
DK (1)	DK0988038T3 (zh)
ES (1)	ES2182327T3 (zh)
HK (2)	HK1025046A1 (zh)
ID (1)	ID24675A (zh)
IL (1)	IL133212A (zh)
NO (1)	NO318834B1 (zh)
NZ (1)	NZ501401A (zh)
PT (1)	PT988038E (zh)
RU (1)	RU2209066C2 (zh)
TR (1)	TR199902923T2 (zh)
WO (1)	WO1998055124A1 (zh)
ZA (1)	ZA984700B (zh)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0988038B1 (en)	1997-06-02	2002-08-14	Janssen Pharmaceutica N.V.	(imidazol-5-yl)methyl-2-quinolinone derivatives as inhibitors of smooth muscle cell proliferation
US20030040790A1 (en) *	1998-04-15	2003-02-27	Furst Joseph G.	Stent coating
US20020099438A1 (en) *	1998-04-15	2002-07-25	Furst Joseph G.	Irradiated stent coating
ID27199A (id) *	1998-07-06	2001-03-08	Janssen Pharmaceutica Nv	Penghambat transferase protein farnesil untuk pengobatan artropatis
US7967855B2 (en)	1998-07-27	2011-06-28	Icon Interventional Systems, Inc.	Coated medical device
US8070796B2 (en)	1998-07-27	2011-12-06	Icon Interventional Systems, Inc.	Thrombosis inhibiting graft
JP3494409B2 (ja) *	1998-08-27	2004-02-09	ファイザー・プロダクツ・インク	抗がん剤として有用なアルキニル置換キノリン−２−オン誘導体
KR100818541B1 (ko) *	1998-12-23	2008-04-02	얀센 파마슈티카 엔.브이.	1,2-어닐링된 퀴놀린 유도체
TR200201297T2 (tr)	1999-02-11	2002-06-21	Pfizer Products Inc.	Antikanser maddeleri olarak faydalı heteroaril-ikame edilmiş kinolin-2-on türevleri.
DK1106612T3 (da) *	1999-11-30	2004-05-17	Pfizer Prod Inc	Quinolinderivater, der er nyttige til inhibering af farnesylproteintransferase
US6844357B2 (en) *	2000-05-01	2005-01-18	Pfizer Inc.	Substituted quinolin-2-one derivatives useful as antiproliferative agents
JO2361B1 (en)	2000-06-22	2006-12-12	جانسين فارماسيوتيكا ان. في	Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
ES2302106T3 (es)	2000-09-11	2008-07-01	Novartis Vaccines And Diagnostics, Inc.	Procedimiento de preparacion de derivados de bencimidazol-2-il quinolina.
FR2813791B1 (fr) *	2000-09-14	2004-03-12	Lafon Labor	Utilisation de 2- et 4-quinolones pour inhiber la neo-proliferation intimale
US7173040B2 (en)	2000-09-25	2007-02-06	Janssen Pharmaceutica N.V.	Farnesyl transferase inhibiting 6-[(substituted phenyl)methyl]-quinoline and quinazoline derinazoline derivatives
EP1322635B1 (en)	2000-09-25	2006-03-22	Janssen Pharmaceutica N.V.	Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors
JP4974439B2 (ja)	2000-09-25	2012-07-11	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	ファルネシルトランスフェラーゼを阻害する６−ヘテロシクリルメチルキノリノン誘導体
AU2002220559A1 (en)	2000-09-25	2002-04-02	Janssen Pharmaceutica N.V.	Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives
DE60139080D1 (de)	2000-11-21	2009-08-06	Janssen Pharmaceutica Nv	Farnesyltransferase hemmende benzoheterocyclische derivate
US7129356B2 (en)	2000-12-27	2006-10-31	Janssen Pharmaceutica N.V.	Farnesyl transferase inhibiting 4-substituted quinoline and quinazoline derivatives
EP1408971A4 (en)	2001-06-21	2006-01-25	Ariad Pharma Inc	NEW QUINOLINES AND THEIR USES
WO2003051880A1 (en)	2001-12-19	2003-06-26	Janssen Pharmaceutica N.V.	1,8-annelated quinoline derivatives substituted with carbon-linked triazoles as farnesyl transferase inhibitors
US7354932B2 (en)	2001-12-21	2008-04-08	Anormed, Inc.	Chemokine receptor binding heterocyclic compounds with enhanced efficacy
ES2287466T3 (es)	2002-03-22	2007-12-16	Janssen Pharmaceutica N.V.	Derivados de 2-quinolinona y quinazolina de bencilimidazolil sustituidas como inhibidores de la farnesil transferasa.
ATE336496T1 (de)	2002-04-15	2006-09-15	Janssen Pharmaceutica Nv	Farnesyl transferase hemmende tricyclische quinazolinederivate substitutiert mit kohlenstoff-gebundenen imidazolen oder triazolen
US8016881B2 (en)	2002-07-31	2011-09-13	Icon Interventional Systems, Inc.	Sutures and surgical staples for anastamoses, wound closures, and surgical closures
US7825132B2 (en)	2002-08-23	2010-11-02	Novartis Vaccines And Diagnostics, Inc.	Inhibition of FGFR3 and treatment of multiple myeloma
US6638301B1 (en) *	2002-10-02	2003-10-28	Scimed Life Systems, Inc.	Medical device with radiopacity
BR0316229A (pt)	2002-11-13	2005-10-04	Chiron Corp	Métodos de tratamento de câncer e métodos relacionados
US20050154451A1 (en) *	2003-12-18	2005-07-14	Medtronic Vascular, Inc.	Medical devices to treat or inhibit restenosis
US7211108B2 (en) *	2004-01-23	2007-05-01	Icon Medical Corp.	Vascular grafts with amphiphilic block copolymer coatings
US7338949B2 (en) *	2004-01-23	2008-03-04	Janssen Pharmaceutica N.V.	Mycobacterial inhibitors
JP5019884B2 (ja)	2004-02-20	2012-09-05	ノバルティスバクシンズアンドダイアグノスティックス，インコーポレーテッド	炎症プロセスおよび転移プロセスの調節
EP1730113B1 (en) *	2004-03-15	2016-12-28	Genzyme Corporation	Process for the synthesis of a cxcr4 antagonist
EP1744751A4 (en) *	2004-03-18	2010-03-10	Brigham & Womens Hospital	TREATMENT OF SYNUCLEINOPATHIES
US20070293539A1 (en) *	2004-03-18	2007-12-20	Lansbury Peter T	Methods for the treatment of synucleinopathies
US20060106060A1 (en) *	2004-03-18	2006-05-18	The Brigham And Women's Hospital, Inc.	Methods for the treatment of synucleinopathies (Lansbury)
JP2007529555A (ja) *	2004-03-18	2007-10-25	ザブライハムアンドウイメンズホスピタル，インコーポレイテッド	シヌクレイノパチーを治療する方法
WO2005089515A2 (en) *	2004-03-18	2005-09-29	The Brigham And Women's Hospital, Inc.	Methods for the treatment of synucleinopathies
US20050272068A1 (en) *	2004-03-18	2005-12-08	The Brigham And Women's Hospital, Inc.	UCH-L1 expression and cancer therapy
US7063720B2 (en) *	2004-09-14	2006-06-20	The Wallace Enterprises, Inc.	Covered stent with controlled therapeutic agent diffusion
US20060083770A1 (en) *	2004-10-15	2006-04-20	Specialty Coating Systems, Inc.	Medical devices and methods of preparation and use
US20060194821A1 (en) *	2005-02-18	2006-08-31	The Brigham And Women's Hospital, Inc.	Compounds inhibiting the aggregation of superoxide dismutase-1
US7540995B2 (en)	2005-03-03	2009-06-02	Icon Medical Corp.	Process for forming an improved metal alloy stent
US9107899B2 (en)	2005-03-03	2015-08-18	Icon Medical Corporation	Metal alloys for medical devices
US20060200048A1 (en) *	2005-03-03	2006-09-07	Icon Medical Corp.	Removable sheath for device protection
WO2006110197A2 (en)	2005-03-03	2006-10-19	Icon Medical Corp.	Polymer biodegradable medical device
US8323333B2 (en) *	2005-03-03	2012-12-04	Icon Medical Corp.	Fragile structure protective coating
US20060264914A1 (en) *	2005-03-03	2006-11-23	Icon Medical Corp.	Metal alloys for medical devices
US20060201601A1 (en) *	2005-03-03	2006-09-14	Icon Interventional Systems, Inc.	Flexible markers
AU2006249847B2 (en)	2005-05-23	2012-12-20	Novartis Ag	Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts
EP2314295B1 (en)	2005-07-29	2015-01-28	Resverlogix, Inc	Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
WO2007075923A2 (en)	2005-12-23	2007-07-05	Link Medicine Corporation	Treatment of synucleinopathies
US20070148390A1 (en) *	2005-12-27	2007-06-28	Specialty Coating Systems, Inc.	Fluorinated coatings
CN101663262B (zh)	2006-12-01	2014-03-26	百时美施贵宝公司	用于治疗动脉粥样硬化和心血管疾病的作为cetp抑制剂的n-(3-苄基)-2,2-(二苯基)-丙-1胺衍生物
MX2009008099A (es)	2007-02-01	2009-12-14	Resverlogix Corp	Compuestos para la prevencion y tratamiento de enfermedades cardiovasculares.
ES2390323T3 (es) *	2007-05-23	2012-11-08	Allergan, Inc.	Compuestos terapéuticos de ((fenil)imidazolil)metilquinolinilo
WO2009151683A2 (en) *	2008-03-12	2009-12-17	Link Medicine Corporation	Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
KR101629356B1 (ko)	2008-06-26	2016-06-13	리스버로직스 코퍼레이션	퀴나졸리논 유도체의 제조방법
US20100331363A1 (en) *	2008-11-13	2010-12-30	Link Medicine Corporation	Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
AU2009313927A1 (en) *	2008-11-13	2010-05-20	Astrazeneca Ab	Azaquinolinone derivatives and uses thereof
US20110060005A1 (en) *	2008-11-13	2011-03-10	Link Medicine Corporation	Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
CA2747417C (en)	2009-01-08	2017-01-03	Resverlogix Corp.	Compounds for the prevention and treatment of cardiovascular disease
US9238640B2 (en)	2009-03-18	2016-01-19	Resverlogix Corp.	Anti-inflammatory agents
BRPI1014956B8 (pt)	2009-04-22	2021-05-25	Resverlogix Corp	agentes anti-inflamatórios
US8398916B2 (en)	2010-03-04	2013-03-19	Icon Medical Corp.	Method for forming a tubular medical device
JP5992049B2 (ja)	2011-11-01	2016-09-14	レスバーロジックスコーポレイション	置換されたキナゾリノンのための経口速放性製剤
RU2014136226A (ru) *	2012-02-13	2016-04-10	Ф.Хоффманн-Ля Рош Аг	Производные имидазолилкетона в качестве ингибиторов альдостеронсинтазы
EP2909192B1 (en) *	2012-10-16	2017-05-17	Janssen Pharmaceutica NV	Methylene linked quinolinyl modulators of ror-gamma-t
SG11201502935VA (en) *	2012-10-16	2015-09-29	Janssen Pharmaceutica Nv	Phenyl linked quinolinyl modulators of ror-gamma-t
BR112015008515A2 (pt)	2012-10-16	2017-07-04	Janssen Pharmaceutica Nv	moduladores de ror t de quinolinila ligada à heteroarila
WO2014080290A2 (en)	2012-11-21	2014-05-30	Rvx Therapeutics Inc.	Cyclic amines as bromodomain inhibitors
WO2014080291A2 (en)	2012-11-21	2014-05-30	Rvx Therapeutics Inc.	Biaryl derivatives as bromodomain inhibitors
WO2014096965A2 (en)	2012-12-21	2014-06-26	Rvx Therapeutics Inc.	Novel heterocyclic compounds as bromodomain inhibitors
US9328095B2 (en)	2013-10-15	2016-05-03	Janssen Pharmaceutica Nv	Heteroaryl linked quinolinyl modulators of RORgammat
US9403816B2 (en)	2013-10-15	2016-08-02	Janssen Pharmaceutica Nv	Phenyl linked quinolinyl modulators of RORγt
CN105848483A (zh)	2013-10-15	2016-08-10	詹森药业有限公司	RORγt 的喹啉基调节剂
US9221804B2 (en)	2013-10-15	2015-12-29	Janssen Pharmaceutica Nv	Secondary alcohol quinolinyl modulators of RORγt
ES2770727T3 (es)	2013-10-15	2020-07-02	Janssen Pharmaceutica Nv	Moduladores de quinilonila enlazados a alquilo de ROR(gamma)t
US10555941B2 (en)	2013-10-15	2020-02-11	Janssen Pharmaceutica Nv	Alkyl linked quinolinyl modulators of RORγt
US9284308B2 (en)	2013-10-15	2016-03-15	Janssen Pharmaceutica Nv	Methylene linked quinolinyl modulators of RORγt
US11311519B2 (en)	2014-05-01	2022-04-26	Eiger Biopharmaceuticals, Inc.	Treatment of hepatitis delta virus infection
US10076512B2 (en)	2014-05-01	2018-09-18	Eiger Biopharmaceuticals, Inc.	Treatment of hepatitis delta virus infection
CN106535826A (zh)	2014-06-24	2017-03-22	怡康医疗股份有限公司	用于医疗装置的改进的金属合金
WO2016100782A1 (en) *	2014-12-18	2016-06-23	University Of South Carolina	Suppression of neointimal formation following vascular surgery using cdk8 inhibitors
JP6903585B2 (ja)	2015-03-13	2021-07-14	レスバーロジックスコーポレイション	補体関連疾患の治療のための組成物および治療方法
HUE054068T2 (hu)	2015-04-21	2021-08-30	Eiger Biopharmaceuticals Inc	Lonafarnibot és Ritonavirt tartalmazó gyógyszerkészítmények
PT3640345T (pt)	2015-08-17	2021-12-29	Kura Oncology Inc	Métodos de tratamento de doentes com cancro usando inibidores da farnesiltransferase
US10953003B2 (en)	2015-12-14	2021-03-23	X4 Pharmaceuticals, Inc.	Methods for treating cancer
CA3008279A1 (en)	2015-12-14	2017-06-22	X4 Pharmaceuticals, Inc.	Methods for treating cancer
SI3393468T1 (sl)	2015-12-22	2023-01-31	X4 Pharmaceuticals, Inc.	Postopki za zdravljenje bolezni imunske pomanjkljivosti
WO2017151548A1 (en)	2016-03-04	2017-09-08	Mirus Llc	Stent device for spinal fusion
US11337969B2 (en)	2016-04-08	2022-05-24	X4 Pharmaceuticals, Inc.	Methods for treating cancer
JP7084624B2 (ja)	2016-06-21	2022-06-15	エックス４ファーマシューティカルズ，インコーポレイテッド	Ｃｘｃｒ４阻害剤およびその使用
EP3808748A1 (en)	2016-06-21	2021-04-21	X4 Pharmaceuticals, Inc.	Substituted piperidines as cxcr4-inhibitors
US11332470B2 (en)	2016-06-21	2022-05-17	X4 Pharmaceuticals, Inc.	CXCR4 inhibitors and uses thereof
DK3534885T3 (da)	2016-11-03	2021-04-12	Kura Oncology Inc	Farnesyltransferase-inhibitorer til anvendelse i behandling af kræft
US10548889B1 (en)	2018-08-31	2020-02-04	X4 Pharmaceuticals, Inc.	Compositions of CXCR4 inhibitors and methods of preparation and use
CN110204487B (zh) *	2019-06-21	2021-09-28	江南大学	一种喹啉衍生物的合成方法
CN113072490B (zh) *	2021-03-26	2022-08-16	中国海洋大学	一种替吡法尼喹啉酮中间体的高效合成方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE456347B (sv)	1982-02-09	1988-09-26	Ird Biomaterial Ab	Ytmodifierat fast substrat samt forfarande for framstellning derav
US5049403A (en)	1989-10-12	1991-09-17	Horsk Hydro A.S.	Process for the preparation of surface modified solid substrates
US5213898A (en)	1989-10-12	1993-05-25	Norsk Hydro A.S.	Process for the preparation of surface modified solid substrates
US5356433A (en)	1991-08-13	1994-10-18	Cordis Corporation	Biocompatible metal surfaces
JPH07112930A (ja) *	1993-10-14	1995-05-02	Kyowa Hakko Kogyo Co Ltd	血管平滑筋細胞増殖抑制剤
KR19990007865A (ko)	1995-04-19	1999-01-25	스피겔알렌제이	약물 방출용 피복 스텐트
US5607475A (en)	1995-08-22	1997-03-04	Medtronic, Inc.	Biocompatible medical article and method
US5863904A (en)	1995-09-26	1999-01-26	The University Of Michigan	Methods for treating cancers and restenosis with P21
TW349948B (en) *	1995-10-31	1999-01-11	Janssen Pharmaceutica Nv	Farnesyl transferase inhibiting 2-quinolone derivatives
TR199800825T2 (xx) *	1995-12-08	1998-08-21	Janssen Pharmaceutica N.V.	Farnesil protein transferini inhibe eden (imidazol-5-il) metil-2-kinolinon t�revleri.
EP0988038B1 (en)	1997-06-02	2002-08-14	Janssen Pharmaceutica N.V.	(imidazol-5-yl)methyl-2-quinolinone derivatives as inhibitors of smooth muscle cell proliferation

1998
- 1998-05-25 EP EP98928332A patent/EP0988038B1/en not_active Expired - Lifetime
- 1998-05-25 CA CA002290992A patent/CA2290992C/en not_active Expired - Lifetime
- 1998-05-25 ES ES98928332T patent/ES2182327T3/es not_active Expired - Lifetime
- 1998-05-25 PT PT98928332T patent/PT988038E/pt unknown
- 1998-05-25 JP JP50144099A patent/JP4209472B2/ja not_active Expired - Lifetime
- 1998-05-25 IL IL13321298A patent/IL133212A/en not_active IP Right Cessation
- 1998-05-25 DE DE69807222T patent/DE69807222T2/de not_active Expired - Lifetime
- 1998-05-25 AT AT98928332T patent/ATE222104T1/de active
- 1998-05-25 NZ NZ501401A patent/NZ501401A/en not_active IP Right Cessation
- 1998-05-25 RU RU2000100032/14A patent/RU2209066C2/ru active
- 1998-05-25 CN CNB98805700XA patent/CN1231215C/zh not_active Expired - Lifetime
- 1998-05-25 AU AU80207/98A patent/AU740603B2/en not_active Expired
- 1998-05-25 BR BR9810423-3A patent/BR9810423A/pt not_active Application Discontinuation
- 1998-05-25 WO PCT/EP1998/003182 patent/WO1998055124A1/en active IP Right Grant
- 1998-05-25 KR KR10-1999-7010744A patent/KR100517832B1/ko not_active IP Right Cessation
- 1998-05-25 CN CNB2005101163581A patent/CN100525766C/zh not_active Expired - Lifetime
- 1998-05-25 DK DK98928332T patent/DK0988038T3/da active
- 1998-05-25 TR TR1999/02923T patent/TR199902923T2/xx unknown
- 1998-05-28 ID IDW991506A patent/ID24675A/id unknown
- 1998-06-01 ZA ZA9804700A patent/ZA984700B/xx unknown
1999
- 1999-05-25 US US09/445,009 patent/US6365600B1/en not_active Expired - Lifetime
- 1999-12-01 NO NO19995883A patent/NO318834B1/no not_active IP Right Cessation
2000
- 2000-07-08 HK HK00104198A patent/HK1025046A1/xx not_active IP Right Cessation
2001
- 2001-11-28 US US09/996,147 patent/US6743805B2/en not_active Expired - Lifetime
2003
- 2003-06-18 US US10/464,570 patent/US6734194B2/en not_active Expired - Lifetime
2004
- 2004-04-14 US US10/823,862 patent/US7253183B2/en not_active Expired - Lifetime
2006
- 2006-08-16 HK HK06109112.8A patent/HK1088820A1/xx not_active IP Right Cessation

Also Published As

Publication number	Publication date
RU2209066C2 (ru)	2003-07-27
CN1762355A (zh)	2006-04-26
DE69807222D1 (de)	2002-09-19
TR199902923T2 (xx)	2000-11-21
BR9810423A (pt)	2000-10-03
HK1025046A1 (en)	2000-11-03
DE69807222T2 (de)	2003-04-17
US20020091138A1 (en)	2002-07-11
ATE222104T1 (de)	2002-08-15
JP2002503235A (ja)	2002-01-29
ZA984700B (en)	1999-12-01
NZ501401A (en)	2002-03-28
AU740603B2 (en)	2001-11-08
AU8020798A (en)	1998-12-21
US20030229118A1 (en)	2003-12-11
US7253183B2 (en)	2007-08-07
US6365600B1 (en)	2002-04-02
US6734194B2 (en)	2004-05-11
CN100525766C (zh)	2009-08-12
CA2290992C (en)	2008-02-12
CN1231215C (zh)	2005-12-14
NO995883D0 (no)	1999-12-01
ES2182327T3 (es)	2003-03-01
EP0988038B1 (en)	2002-08-14
KR20010012782A (ko)	2001-02-26
JP4209472B2 (ja)	2009-01-14
CN1265585A (zh)	2000-09-06
WO1998055124A1 (en)	1998-12-10
ID24675A (id)	2000-07-27
KR100517832B1 (ko)	2005-09-30
CA2290992A1 (en)	1998-12-10
US20040198771A1 (en)	2004-10-07
DK0988038T3 (da)	2002-12-02
EP0988038A1 (en)	2000-03-29
PT988038E (pt)	2002-12-31
HK1088820A1 (en)	2006-11-17
NO995883L (no)	2000-02-02
US6743805B2 (en)	2004-06-01
NO318834B1 (no)	2005-05-09
IL133212A0 (en)	2001-03-19

Legal Events

Date	Code	Title
2006-07-05	FF	Patent granted
2006-07-05	KB	Patent renewed
2008-08-10	KB	Patent renewed
2012-06-28	KB	Patent renewed
2016-04-21	KB	Patent renewed
2018-12-31	EXP	Patent expired

Publication	Publication Date	Title
EP0988038B1 (en)	2002-08-14	(imidazol-5-yl)methyl-2-quinolinone derivatives as inhibitors of smooth muscle cell proliferation
US6169096B1 (en)	2001-01-02	Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quinolinone derivatives
DE69907964T2 (de)	2004-02-19	1,2-annelierte chinolinderivate
JP2003525234A (ja)	2003-08-26	カンプトテシン化合物とのファルネシルタンパク質トランスフェラーゼ阻害剤の組み合わせ剤
JP2003525244A (ja)	2003-08-26	抗腫瘍性アルキル化剤とのファルネシルタンパク質トランスフェラーゼ阻害剤組み合わせ剤
JP2003525239A (ja)	2003-08-26	タキサン化合物とのファルネシルタンパク質トランスフェラーゼ阻害剤の組み合わせ剤
US20040157882A1 (en)	2004-08-12	Method of use of (imidazol-5-yl)methyl-2-quinolinone derivatives to inhibit smooth muscle cell proliferation
MXPA99011128A (en)	2001-12-04	(imidazol-5-yl)methyl-2-quinolinone derivatives as inhibitors of smooth muscle cell proliferation
PL190618B1 (pl)	2005-12-30	Zastosowanie (+)-6-[amino-(4-chlorofenylo) (1 -metylo-1 H-imidazol-5-ilo)metylo]-4-(3-chlorofenylo)-1-metylo-2(1H)-chinolinonu lub jego farmaceutycznie dopuszczalnej soli addycyjnej z kwasem